Equity Capital: 118.28 Cr FV: 10.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 15,612.36 | -19,132.24 |
LAST 3M | 53,075.98 | -4,241.70 |
LAST 6M | 58,662.39 | 138,824.89 |
LAST 12M | 133,944.68 | 162,473.45 |
Date | Action Type | Ratio |
---|---|---|
Sep 16, 2022 | Dividend | 2.5 |
Sep 15, 2021 | Dividend | 2.5 |
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in `catalyst chemistry` and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Company`s marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise, this product fits in product selection criteria, through which the Company is confident of grabbing significant market share. Due to floods and fire in the company units, the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed, Ratnagiri. The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. The Company is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team, which is guided by these values, is well positioned to lead into the future. The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today, the Company is the leading manufacturer player in veterinary APIs in India, with a well-established brand known for its high-quality products amongst various customers.
C-105 MIDC, Mahad, Raigad, Maharashtra, 402301
Tel | : | 91-2145-232101/232202 |
: | cs:lasalabs.com | |
Website | : | http://www.lasalabs.com |
Bigshare Services Pvt Ltd
AGM Date (Month) | : | Sep |
Face Value Equity Shares | : | 10 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 540702 |
NSE Code | : | LASA |
Book Closure Date (Month) | : | Sep |
BSE Group | : | T |
ISIN | : | INE670X01014 |
You can buy Lasa Supergenerics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lasa Supergenerics Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Oct 04, 2023 03:33 PM the closing price of Lasa Supergenerics Ltd was ₹ 26.05.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 04, 2023 03:33 PM, the market cap of Lasa Supergenerics Ltd stood at ₹ 130.51.
The latest PE ratio of Lasa Supergenerics Ltd as of Oct 04, 2023 03:33 PM is 0
The latest PB ratio of Lasa Supergenerics Ltd as of Oct 04, 2023 03:33 PM is 0.91
The 52-week high of Lasa Supergenerics Ltd is ₹ 38.90 while the 52-week low is ₹ 17.10